氟达拉滨联合米托蒽醌与CHOP方案治疗恶性淋巴瘤的疗效比较

Clinical Effect Comparison Between Fludarabine Combined with Mitoxantrone and CHOP Scheme for Treatment of Malignant Lymphoma(ML)

目的探析恶性淋巴瘤应用氟达拉滨联合米托蒽醌(FND)与CHOP方案治疗的临床效果对比。方法入选该院恶性淋巴瘤患者64例,随机分为两组各32例,观察组进行FND化疗方案,对照组施行CHOP化疗方案,比较两组的临床效果及化疗方案副反应。结果观察组的临床总有效率显著高于对照组(P<0.05),观察组不良反应主要以骨髓抑制为主,对照组的主要副反应是消化道不适,观察组的化疗方案不良反应显著低于对照组(P<0.05)。结论恶性淋巴瘤施行氟达拉滨联合米托蒽醌化疗方案,临床效果确切,化疗不良反应可以耐受,可靠安全,值得临床推广。

Objective To compare the clinical effect between fludarabine combined with mitoxantrone （FDN） and CHOP scheme for the treatment of ML. Methods 64 cases of patients with ML admitted in our hospital were selected and randomly divided into 2 groups, both with 32 cases. The observation group was given FND chemotherapy scheme while the control group was given CHOP chemotherapy. The clinical effects and side effects of the 2 groups were compared. Results The total effective rate of the observa-tion group was obviously higher than that of the control group （P〈0.05）. Adverse reactions of the observation group was mainly myelosuppression while that of the control group was mainly digestive discomfort. Adverse reactions of observation group were ob-viously fewer than those of control group （P〈0.05）. Conclusion FDN chemotherapy scheme for the treatment of ML has accurate clinical effects and tolerable side effects. It＆#39;s safe and reliable and worthy of being popularized in clinical work.